736 related articles for article (PubMed ID: 31848196)
1. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
[TBL] [Abstract][Full Text] [Related]
2. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
Front Immunol; 2021; 12():645170. PubMed ID: 33897693
[TBL] [Abstract][Full Text] [Related]
3. Frameshift events predict anti-PD-1/L1 response in head and neck cancer.
Hanna GJ; Lizotte P; Cavanaugh M; Kuo FC; Shivdasani P; Frieden A; Chau NG; Schoenfeld JD; Lorch JH; Uppaluri R; MacConaill LE; Haddad RI
JCI Insight; 2018 Feb; 3(4):. PubMed ID: 29467336
[TBL] [Abstract][Full Text] [Related]
4. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
[TBL] [Abstract][Full Text] [Related]
6. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Aggarwal C; Cohen RB; Morrow MP; Kraynyak KA; Sylvester AJ; Knoblock DM; Bauml JM; Weinstein GS; Lin A; Boyer J; Sakata L; Tan S; Anton A; Dickerson K; Mangrolia D; Vang R; Dallas M; Oyola S; Duff S; Esser M; Kumar R; Weiner D; Csiki I; Bagarazzi ML
Clin Cancer Res; 2019 Jan; 25(1):110-124. PubMed ID: 30242022
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
Front Immunol; 2021; 12():652054. PubMed ID: 34305889
[TBL] [Abstract][Full Text] [Related]
9. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
10. SLC7A11 as a biomarker and therapeutic target in HPV-positive head and neck Squamous Cell Carcinoma.
Hémon A; Louandre C; Lailler C; Godin C; Bottelin M; Morel V; François C; Galmiche A; Saidak Z
Biochem Biophys Res Commun; 2020 Dec; 533(4):1083-1087. PubMed ID: 33019976
[TBL] [Abstract][Full Text] [Related]
11. The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation.
Yu D; Liu X; Han G; Liu Y; Zhao X; Wang D; Bian X; Gu T; Wen L
Cell Commun Signal; 2019 Dec; 17(1):173. PubMed ID: 31881947
[TBL] [Abstract][Full Text] [Related]
12. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
14. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
Front Immunol; 2019; 10():1644. PubMed ID: 31379843
[No Abstract] [Full Text] [Related]
15. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
16. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
17. [Current events in immunotherapy for upper aerodigestive tract cancer].
Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
Park SJ; Ye W; Xiao R; Silvin C; Padget M; Hodge JW; Van Waes C; Schmitt NC
Oral Oncol; 2019 Aug; 95():127-135. PubMed ID: 31345380
[TBL] [Abstract][Full Text] [Related]
19. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
20. Integrin β4-Targeted Cancer Immunotherapies Inhibit Tumor Growth and Decrease Metastasis.
Ruan S; Lin M; Zhu Y; Lum L; Thakur A; Jin R; Shao W; Zhang Y; Hu Y; Huang S; Hurt EM; Chang AE; Wicha MS; Li Q
Cancer Res; 2020 Feb; 80(4):771-783. PubMed ID: 31843981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
